Cost effectiveness of omalizumab for severe asthma in Colombia

Figures & data

Figure 1. Markov model.

OCS: Oral corticosteroids systemic

Table 1. Base case.

Variable	Base case	Valor high	Valor low	References
Cost US$
Cost Omalizumab (per 4-week cycle)	$ 911	$ 1.139	$ 683	13
Cost controlled (annual)	$ 2.244	$ 2.805	$ 1.683
Cost OCS burst (per episode)	$ 195	$ 244	$ 146
Cost ED visit (per episode)	$ 228	$ 285	$ 171
Cost hospitalization (per episode)	$ 4.635	$ 5.794	$ 3.477
Utilities (annual)
Asthma non exacerbation state	0.74	0,8	0,5	12
Utility decrement
Exacerbations requiring OCS burst	0,1	0,2	0,05	13
Exacerbations requiring ED visit	0,15	0,3	0,1
Exacerbations requiring hospitalization	0,2	0,3	0,1
Omalizumab effect
Relative risk on exacerbation requiring OCS burst	0,56	0,7	0,42	4
Relative risk on exacerbations requiring ED visit	0,72	0,9	0,54
Exacerbations
Exacerbation annual rate	1,1	4	1	13
# Hospitalization annual	2,6	5	1
Adherence	0,774	0,9	0,55	11
Responding rate on Omalizumab	0,605	0,8	0,55	12

OCS: Oral corticosteroids systemic.

Table 2. Result of cost effectiveness analysis.

Mean inc. Effect per person (QALY)	0.094
Mean inc. Cost per person (US$)	3481
Probability intervention is cost saving	0.033
Probability intervention provides more benefit	0.88
Probability that intervention is cost-effective against comparator	0.033
Expected net benefit at US$ 5180 per QALY of Omalizumab	20116
Expected net benefit at US$ 5180 per QALY of no Omalizumab	23108

Figure 2. Tornado diagram.

Figure 3. Cost effectiveness plane.

WTP: Willingness-to-pay.

Figure 4. Cost-effectiveness acceptability curve.

Einarson TR, Bereza BG, Nielsen TA, Hemels ME. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550–563. doi:10.3111/13696998.2015.1025793.

 PubMed Web of Science ®Google Scholar

Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–1492. doi:10.1016/j.rmed.2007.01.011.

 PubMed Web of Science ®Google Scholar

Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221.

 PubMed Web of Science ®Google Scholar

Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, Griffin NM, Chipps BE. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract. 2019;7(1):156–164 e1. doi:10.1016/j.jaip.2018.04.043.

 PubMed Web of Science ®Google Scholar

Data availability statement

BD CU Omalizumab [Data set]. Zenodo. http://doi.org/10.5281/zenodo.4700232.